{
  "paper_id": "0f6a5070fd5f9bd5d46c3bbd4545c55982e726c3",
  "metadata": {
    "title": "Type 1 interferons as a potential treatment against COVID-19",
    "coda_data_split": "dev",
    "coda_paper_id": 1817,
    "coda_has_expert_labels": false,
    "subset": "custom_license"
  },
  "abstract": [
    {
      "original_text": "Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.",
      "sentences": [
        [
          {
            "segment_text": "Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "In this review , we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2 ,",
            "crowd_label": "purpose"
          },
          {
            "segment_text": "and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19 .",
            "crowd_label": "purpose"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "1",
    "sentence_num": "2",
    "segment_num": "3",
    "token_num": "57"
  }
}